| 查看: 186 | 回复: 0 | |||
ienjoysun银虫 (著名写手)
|
[交流]
Novartis in talks to buy Gamida Cell for up to $600 million: report
|
|
Novartis in talks to buy Gamida Cell for up to $600 million: report (Ref: Globes, Jewish Business News, Fidelity) March 18th, 2014 By: Matthew Dennis Tags: Top Story StemEx Clal Biotechnology Gamida Cell Novartis Corporate Affairs Mergers & Acquisitions According to sources close to the matter, Novartis is in advanced discussions to buy Gamida Cell for as much as $600 million, Globes reported Tuesday. Elbit Medical Technologies, which has a 30.8-percent stake in Gamida, confirmed an offer from an unnamed company, noting that it includes a "significant immediate payment and additional future payments totalling hundreds of millions of dollars." Clal Biotechnology, which holds around 22 percent of Gamida, added that the bid was received on March 7. Gamida is developing stem cell therapies for a variety of conditions, including its StemEx treatment, which is being evaluated as part of a transplant regimen for patients with high-risk leukaemia and lymphoma. According to Elbit and Clal, future payments under the deal would depend on meeting development, registration and sales milestones. Globes noted that although talks with Novartis are at an advanced stage, Gamida has not abandoned plans for an initial public offering. The newspaper said that the valuation for the IPO is lower than the potential value of an acquisition, which would likely be the preferred option. http://www.firstwordpharma.com/node/1196136#axzz2wOds3Uam |
回复此楼» 猜你喜欢
🔥速览｜AACR 2026 mRNA肿瘤疫苗临床捷报
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有128人回复
-
分子对接相关经验分享
已经有0人回复
-
深圳理工大学和东南大学联合培养博士招生（2026年9月入学）
已经有11人回复
-
211高校2026年入学博士名额
已经有14人回复
-
211高校2026年入学博士名额
已经有15人回复
-
211高校2026年入学博士名额
已经有16人回复
-
海勃原辅料助力银屑病一线外用制剂开发
已经有0人回复
